LXR Biotechnology has halted US clinical trials of Lexirin in AIDSpatients, and is to refocus its resources into the development of candidate systems for the preservation and protection of organ function. The decision was made in light of the increased use of triple-drug combination therapy over the past six-to-nine months, and the corresponding decrease in side effects experienced by patients with HIV and AIDS, it says.
Lexirin works by inhibiting excessive apoptotic cell death in the gastrointestinal tract, usually associated with severe diarrhea in
patients receiving cancer chemotherapy, radiotherapy for prostate cancer, and in AIDS. The decision to rechannel resources was made despite the fact that preclinical studies showed that Lexirin protects cells from apoptosis in the intestinal lining, and that preliminary results of the recent Phase I trial demonstrated that the drug was well-tolerated by patients, with no adverse events.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze